Dr. Lane’s research focuses on the biology of high-risk hematologic malignancies, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and blastic plasmacytoid dendritic cell neoplasm (BPDCN), to identify novel therapeutic targets and to understand treatment resistance. He has also identified cancer genes including tumor suppressors that escape X inactivation (EXITS genes) as mediators of sex bias in tumor genomes. 

He is Chief of the Division of Hematologic Neoplasia at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. He leads the Leukemia Program for the Harvard Cancer Consortium and is Director of the BPDCN Center at Dana-Farber. He is also an associate member of the Broad Institute of Harvard and MIT. 

Dr. Lane received a bachelor’s degree in biomedical engineering from Vanderbilt University, and MD and PhD degrees from Washington University. He completed a residency in internal medicine at Brigham and Women’s Hospital and fellowships in hematology and medical oncology at the Dana-Farber Cancer Institute.